NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Earnings for NATCO Pharma Limited (NATCOPHARM.NS)
Earnings in 2023 (TTM): $198.27 M
According to NATCO Pharma Limited's latest financial reports the company's current earnings (TTM) are $198.27 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of NATCO Pharma Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $198.27 M | $164.48 M |
| 2022 | $102.12 M | $84.75 M |
| 2021 | $23.96 M | $20.14 M |
| 2020 | $68.67 M | $52.24 M |
| 2019 | $67.38 M | $54.59 M |
| 2018 | $97.71 M | $76.35 M |
| 2017 | $105.11 M | $82.48 M |
| 2016 | $73.98 M | $57.58 M |
| 2015 | $24.48 M | $18.38 M |
| 2014 | $15.9 M | $15.95 M |
| 2013 | $15.28 M | $12.17 M |
| 2012 | $12.12 M | $8.51 M |
| 2011 | $9.42 M | $7.06 M |
| 2010 | $7.72 M | $6.34 M |
| 2009 | $7.48 M | $5.77 M |
| 2008 | $6.71 M | $5.21 M |
| 2007 | $6.55 M | $4.8 M |
| 2006 | $4.71 M | $3.61 M |
| 2005 | $3.22 M | $2.82 M |
| 2004 | $88.82 K | $184.45 K |